首页 | 本学科首页   官方微博 | 高级检索  
检索        

重组腺病毒载体介导血管抑素基因治疗裸鼠卵巢癌的实验研究
引用本文:贾长茹,YANG Shu-yan,韩世愈,SUN Lei.重组腺病毒载体介导血管抑素基因治疗裸鼠卵巢癌的实验研究[J].中华医学杂志,2008,88(31):2204-2208.
作者姓名:贾长茹  YANG Shu-yan  韩世愈  SUN Lei
作者单位:1. 哈尔滨医科大学附属第四医院妇产科,150001
2. Department of Obstetrics and Gynecology,Fourth Hospital of Harbin Medical University, Harbin 150001, China
摘    要:目的 构建携带血管抑素(AG)基因K(1-3)重组复制缺陷型腺病毒表达载体,研究腺病毒介导的人血管抑素基因对卵巢癌的治疗作用.方法 (1)将人血管抑素K(1-3)cDNA插入穿梭载体pShuttle产生重组质粒pShttle-AG(K1-3),经双酶切与骨架载体pAdeno-X重组产生pAdeno-X-AG(K1-3),转染293细胞制备重组腺病毒.(2)建立人卵巢癌裸鼠动物模型,检测腺病毒介导的人血管抑素基因对肿瘤生长的抑制作用.结果 3个实验组中,Ad-AG(K1-3)组肿瘤的体积和重量显著小于PBS和Ad-LacZ组(P<0.01),而PBS和Ad-LacZ组之间肿瘤体积和重量差异无统计学意义(P>0.05).PBS组和Ad-LacZ组肿瘤组织中CD34及VEGF表达差异无统计学意义(P>0.05),与对照组相比Ad-AG(K1-3)组中CD34及VEGF表达明显降低(P<0.01).结论 成功包装出重组腺病毒介导的人血管抑素基因在体内、体外均高效表达,并明显抑制人卵巢癌裸鼠移植瘤的肿瘤血管生成和肿瘤生长,为其治疗卵巢癌的临床应用奠定了基础.

关 键 词:腺病毒载体  血管抑素  卵巢癌  基因治疗

Adenovirus mediated angiostatin gene therapy for ovarian cancer: experiment with nude mice
JIA Chang-ru,YANG Shu-yan,HAN Shi-yu,SUN Lei.Adenovirus mediated angiostatin gene therapy for ovarian cancer: experiment with nude mice[J].National Medical Journal of China,2008,88(31):2204-2208.
Authors:JIA Chang-ru  YANG Shu-yan  HAN Shi-yu  SUN Lei
Abstract:Objective To built an expression vector of angiostatin (AG) gene with recombinated replication defective adenovirus and investigate the therapeutic effect of human AG gene on ovarian cancer. Methods (1) Human AG K ( 1-3 ) cDNA was inserted into the vector pShuttle to build the recombinant plasmid pShttle-AG ( K1-3 ). pAdeno-X-AG (K1-3) was built by double-cut and recombinated pShttle-AG (K1-3) to vector pAdeno-X, and then recombinant adenovirus was finally prepared by transinfection of pAdeno-X-AG (K1-3) into to the human embryo kidney cells of the line 293. (2) Human ovarian cancer cells of the line SKOV3 were inoculated subcutaneously into nude mice of the line BALB/c nu/nu to establish model of human ovarian cancer. Then the mice were randomly divided into 3 groups to be injected with Ad = AG (K1-3), Ad-LacZ, or phosphate buffered saline (PBS) around the cancer every 5 days. The tumor size was measured every 5 days to calculate the tumor volume and tumor inhibition rate. Three days after the last injection the mice were killed. The tumor tissues, livers, and kidneys of the mice underwent imunohistochemistry to calculate the microvessel density (MVD) and expression of vessel endothelial growth factor (VEGF) and AG. Results The tumor volume and weight of the Ad-AG ( K1-3 ) group were significantly less than those of the PBS and Ad-LacZ groups ( all P <0. 01 ), however, there were not significant difference between the latter two groups ( both P > 0. 05). The expression levels of CD34 and VEGF of the Ad-AG( K1-3 ) group were both significantly lower than those of the PBS and Ad-LacZ groups (all P < 0. 01 ), however ( both P > 0. 05 ). Conclusion Human angiostatin mediated by adenovirus suppresses the angiogenesis and the growth of human ovarian cancer in the nude mice model, which suggests that it is promising in clinical application.
Keywords:Adenovirus vector  Angiostatin  Ovarian cancer  Gene therapy
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号